Ignite Creation Date:
2024-05-05 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00237913
Status:
COMPLETED
Last Update Posted:
2013-11-08
First Post:
2005-10-11
Brief Title:
Schizophrenia Trial of Aripiprazole
Sponsor:
Otsuka Pharmaceutical Development Commercialization Inc
Organization:
Otsuka Pharmaceutical Development Commercialization Inc
Study Overview
Official Title:
A Multicenter Randomized Naturalistic Open-Label Study Between Aripiprazole and Standard of Care in the Management of Community-Treated Schizophrenic Patients Schizophrenia Trial of Aripiprazole - STAR
Status:
COMPLETED
Status Verified Date:
2008-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Aripiprazole will show improved effectiveness over the standard of care treatment with one of three atypical antipsychotics olanzapine quetiapine and risperidone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None